On Monday, dozens of healthcare providers have agreed to make fewer medical procedures subject to prior authorization while also agreeing to speed up the process. Insures are also pledging to use clearer language when communicating with patients and promised that medical professionals would review coverage denials. Keep in mind that this is not mandated by any law. This agreement does not spell out how it would would help the sickest patients or those who need expensive treatment. Most of this isn't new and some of the agreements have already been in place or required, such as under the ACA. Additionally, insurers are going to make more use of AI to help speed up the prior authorization process. The key take away is; the prior authorizations are not going away, but perhaps the process can be more efficient.

Your Feed
Filter by
See content from
Playlist: EHA 2025
The Importance of Joining Clinical Trials | Sunil Gupta, FCRPath, MRCP, DNB | EHA 2025 #myeloma
Video details & playlist
Playlist: EHA 2025
The Importance of Joining Clinical Trials | Sunil Gupta, FCRPath, MRCP, DNB
Video details & playlist
Playlist: EHA 2025
Diagnosing Myeloma? Don’t Skip This Critical Amyloidosis Test! Jahanzaib Khwaja, MD, FRCPath
Video details & playlist
Playlist: Managing Toxicities of T-cell Redirection
What is immune effector cell associated hematotoxicity (ICHAT)? Which myeloma therapies are associated with ICHAT? How is ICHAT managed?
Video details & playlist
Playlist: EHA 2025
New Hope for MRD Recurrence? Daratumumab Proof-of-Concept Study | Krzysztof Jamroziak, MD | #EHA2025
Video details & playlist
Playlist: Autologous Stem Cell Transplant (ASCT)
What should I know abut visitors during the ASCT process?
Video details & playlist
Playlist: EHA 2025
Venetoclax for AML: Shifting Care from Hospital to Clinic | Aaron Goldberg, MD, PhD | #EHA2025
Video details & playlist
Playlist: EHA 2025
Less Time in the Hospital: Real-World Benefits of Venetoclax for AML Patients | Aaron Goldberg, MD | #EHA2025
Video details & playlist
Playlist: EHA 2025
Promising New Combo Treatment Shows High Remission Rates in AML Patients with NPM1 and KMT2A Mutations | Harry Erba, MD | #EHA2025
Video details & playlist
Playlist: EHA 2025
Hope for Relapsed AML: Ziftomenib Shows Promise in NPM1-Mutated Leukemia | Eunice Wang, MD | #EHA2025
Video details & playlist
Playlist: EHA 2025
Unmet Medical Needs of Patients Who are Lenalidomide Refractory | Claudio Cerchione, MD | #EHA2025
Video details & playlist
Playlist: EHA 2025
Could Clonotypic B Cells Be the Key to Myeloma & AL Amyloidosis Origins? | Bruno Paiva, PhD | EHA25
Video details & playlist

